Pacific Edge slumps 89.9% on Novitas decision

Pacific Edge slumps 89.9% on Novitas decision
The company still believes that it can still deliver. (Image: Pacific Edge).
Rebecca Howard
Shares of Pacific Edge plunged 89.9% on news that Medicare coverage of Cxbladder tests in the US is expected to cease from July 17.The shares resumed trading at 5 cents, having been halted on Tuesday at 49.5 cents while management worked through the implications of the decision.That wiped out $360.6 million of value as investors put a market price of $40.5m on Pacific Edge.  Over the coming days Pacific Edge will seek to explore all available legal options, including a potential appeal, with its US-based lawyers, the company said.A so-call...

More Markets

NZ sharemarket starts week up 0.6%
Markets Market Close

NZ sharemarket starts week up 0.6%

The S&P/NZX 50 Index closed at 13,449.85, up 80.45 points or 0.6%.

Kiwi Property Group's interim profit lower as write-downs bite
Economy

Kiwi Property Group's interim profit lower as write-downs bite

The property company reiterates its full-year dividend views.

Gentrack in the hunt for 10 new customers
Markets

Gentrack in the hunt for 10 new customers

Shares climb more than 14% on hopes of at least three or four new customers.  

Another solar farm gets the nod from Genesis
Markets

Another solar farm gets the nod from Genesis

Genesis Energy has approved the construction of the Edgecumbe Solar Farm in the Bay of Plenty, marking its second major solar commitment in as many months.The company made a final investment decision (FID) on the 136 megawatt peak (MWp) farm, clearing the way for work to begin sh...